Tandem Diabetes Care | TNDM - Selling And Administration Expenses


Tandem Diabetes Care reported $111.64M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Abbott USD 4.27B 669M Sep/2026
Accuray USD 124.78M 2.54M Dec/2025
Align Technology USD 410.55M 52.12M Sep/2026
AtriCure USD 82.56M 1.99M Jun/2026
Baxter International USD 735M 7M Jun/2026
Becton, Dickinson and Co. USD 1.26B 48M Jun/2026
Boston Scientific USD 1.68B 120M Sep/2026
Cooper Companies USD 401.3M 274.9M Jun/2026
Dexcom USD 358.7M 9M Jun/2026
Edwards Lifesciences USD 561.2M 39M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Globus Medical USD 286.82M 10.95M Jun/2026
ICU Medical USD 151.92M 2.64M Jun/2026
Inogen USD 43.77M 510K Jun/2024
Insulet USD 344.8M 27.6M Jun/2026
Integra LifeSciences USD 161.02M 5.2M Sep/2026
Intuitive Surgical USD 1.08B 465.5M Sep/2026
J&J USD 6.25B 168M Sep/2026
Medtronic 3.2B 141M Jun/2026
Merit Medical Systems USD 129.23M 18.76M Jun/2026
Orthofix International USD 130.35M 11.31M Dec/2025
Roche Holding CHF 6.37B 908M Jun/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 111.64M 3.45M Jun/2026
Teleflex USD 213.52M 12.5M Jun/2026
Zimmer Biomet Holdings USD 911.6M 61.7M Jun/2026